RxDoctor Payments Data

Jobse Lebron, MD

General Practice · Fajardo, PRNPI 1427367077

Payments from drug & device makers

$1,092in general payments, 2019–2025

Across 44 payments — averaging $24.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$344
  • Lilly USA, LLC$161
  • Novartis$125
  • Redhill Biopharma Inc.$71
  • Boehringer Ingelheim$62
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$58
  • plus $270 from 9 others

What the payments were for

  • Food & beverage$1,092100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,092 in reported general payments places this provider in the 85th percentile of 3,586 general practice providers in Puerto Rico.

See all general practice providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$6,647
Medicare patients
25
Services billed
107

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban131$109,448
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$22,005
JardianceEmpagliflozin17$13,732
JanuviaSitagliptin Phosphate16$11,751
Tresiba Flextouch U-100Insulin Degludec20$9,945
Fluticasone-SalmeterolFluticasone Propion/Salmeterol82$9,262
Albuterol Sulfate HfaAlbuterol Sulfate251$7,587
Atorvastatin Calcium847$7,302
Gabapentin378$6,606
Wixela InhubFluticasone Propion/Salmeterol43$4,450
Novolog FlexpenInsulin Aspart13$4,305
Amiodarone Hcl38$4,037
Levothyroxine Sodium301$3,636
Memantine Hcl108$3,255
Losartan Potassium338$2,679

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$43$109,448131 claims
GSKTrelegy Ellipta$344$22,00523 claims
Boehringer IngelheimJardiance$62$13,73217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,586 general practice providers in Puerto Rico.

Other general practice in Fajardo

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →